



Date of submission: December 7, 2024

To, The Secretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code – 539551	To, The Secretary Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051 Scrip Code- NH
---	---

Dear Sir/Madam,

Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), we wish to inform you that Health City Cayman Islands Ltd. (HCCI), a wholly owned overseas subsidiary of the Company has infused an amount of USD 1.5 Million in Cayman Integrated Healthcare Limited (CIHL), a wholly-owned overseas subsidiary of HCCI and a step-down subsidiary of the Company by way of subscription to its equity shares equivalent to USD 1.5 Million, i.e., 150,000 ordinary shares in the capital of the Company, each as fully paid, with the value of each ordinary shares being set at US\$ 10.00, which is comprised US\$0.01 of par value and US\$ 9.99 of share premium. The above-mentioned shares have been allotted by CIHL to HCCI on December 6, 2024 (Friday). With this investment, the total investment of HCCI in CIHL stands at USD 5,550,000.

Further, the details as required under SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as Annexure.

Kindly take the same on record.

Thanking you

Yours faithfully
For **Narayana Hrudayalaya Limited**

Sridhar S.
Group Company Secretary, Legal & Compliance Officer

Annexure- Details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular Nos. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 and SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sl. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	<p>Cayman Integrated Healthcare Limited</p> <p>Cayman Integrated Healthcare Limited is a wholly-owned overseas subsidiary of Health City Cayman Islands Ltd and a step-down subsidiary of the Company and having its registered office at Cayman Islands.</p> <p>*Paid up share capital: USD 55,50,000 (USD 5,550 as Share Capital and USD 55,44,450 as share premium)</p> <p>*Turnover (Gross earned revenue) for FY 2025 (upto November): USD 1.32 Mn</p>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	<p>The transaction involves subscription of equity shares by Health City Cayman Islands Ltd, a wholly owned overseas subsidiary of the Company in Cayman Integrated Healthcare Limited, a wholly-owned overseas subsidiary of Health City Cayman Islands Ltd and a step-down subsidiary of the Company. The transaction is a related party transaction. However, it may be noted that it is a transaction between a holding Company and its wholly owned subsidiary whose accounts are consolidated with the ultimate Holding Company.</p> <p>The promoter / promoter group / group companies of the Company do not have any interest in the said transaction. Further, the said transaction is on arm’s length basis.</p>
3.	Industry to which the entity being acquired belongs	Health Insurance
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The infusion of funds by Health City Cayman Islands Ltd in Cayman Integrated Healthcare Limited, by way of subscription to its equity shares, is for the purpose of meeting the working capital requirements of the overseas subsidiary.
5.	Brief details of any Governmental or regulatory approvals required for the Acquisition	None. Existing wholly owned subsidiary.
6.	Indicative period for completion of the acquisition	Not applicable. Existing wholly owned subsidiary.

Sl. No.	Particulars	Details								
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration								
8.	Cost of acquisition and/or the price at which the shares are acquired;	Total investment in the step down subsidiary is USD 5.55 Million (USD 5,550,000): 55,50,000 ordinary shares in the capital of the Company, each as fully paid, with the value of each ordinary being set at US\$ 10.00, which is comprised US\$0.01 of par value and US\$ 9.99 of share premium.								
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	100%								
10.	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Cayman Integrated Healthcare Limited was incorporated on September 28, 2022 and has its registered office at Cayman Islands.</p> <p>The details of turnover for the last two* financial years are as follows:</p> <table border="1"> <thead> <tr> <th>Financial Year</th> <th>Turnover</th> </tr> </thead> <tbody> <tr> <td>2024-25</td> <td>(Gross earned revenue): USD 1.32 Mn till November 2024.</td> </tr> <tr> <td>2023-24</td> <td>NIL</td> </tr> <tr> <td>2022-23</td> <td>NIL</td> </tr> </tbody> </table> <p>*Date of incorporation September 28, 2022.</p>	Financial Year	Turnover	2024-25	(Gross earned revenue): USD 1.32 Mn till November 2024.	2023-24	NIL	2022-23	NIL
Financial Year	Turnover									
2024-25	(Gross earned revenue): USD 1.32 Mn till November 2024.									
2023-24	NIL									
2022-23	NIL									